Teva Attacks Watson Over Generic Menopause Drug

Law360, New York (April 27, 2010, 12:33 PM EDT) -- Teva Women’s Health Inc. has filed a patent infringement suit over Watson Pharmaceuticals Inc.'s plan to introduce a generic version of menopause drug Cenestin.

Teva submitted its complaint Friday in the U.S. District Court for the District of New Jersey after learning of Watson’s intentions to market synthetic conjugated estrogen oral tablets, the generic name for Cenestin.

Cenestin is used to reduce common menopause symptoms such as hot flashes and vaginal dryness, as well as to prevent bone loss in aging women. The drug had sales...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.